Retosiban
| CAS No. | 820957-38-8 | Cat. No. | BCP46037 |
| Name | Retosiban | ||
| Synonyms | GSK-221149A; GSK 221149A; GSK221149A;GSK 221149;GSK221149;GSK-221149; | ||
| Formula | C27H34N4O5 | M. Wt | 494.58 |
| Description | Retosiban is an oral active, potent and selective, sub-nanomolar (Ki = 0.65 nM) oxytocin receptor antagonist with >1400-fold selectivity over the related vasopressin receptors. Retosiban inhibits the procontractile effect of stretch on human myometrium. retosiban prevented stretch-induced stimulation of human myometrial contractility. Retosiban treatment is a potential approach for preventing preterm birth in multiple pregnancy. Retosiban is being developed by GlaxoSmithKline for the treatment of preterm labour. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Oxytocin Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.